

- Agustina, J., Sinulingga, D., Suzanna, E., Andinata, B., Ramadhan, R. and Kadir, A., 2018. Epidemiology of Female Breast Cancer in West Jakarta, Indonesia. *Journal of Global Oncology*, 4(Supplement 2), pp.65s-65s.
- Akram, M., Iqbal, M., Daniyal, M. and Khan, A., 2017. Awareness and current knowledge of breast cancer. *Biological Research*, 50(1).
- Alkabban, F. and Ferguson, T., 2019. *Breast Cancer*. StatPearls Publishing.
- Al Jarroudi, O., Abda, N., Seddik, Y., Brahmi, S. and Afqir, S., 2017. Overweight: Is It a Prognostic Factor in Women with Triple-Negative Breast Cancer?. *Asian Pacific Journal of Cancer Prevention*, 18(6), pp. 1519-1523.
- Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O. and Minko, T., 2018. Metastatic and triple-negative breast cancer: challenges and treatment options. *Drug Delivery and Translational Research*, 8(5), pp.1483-1507.
- Aysola, K., Desai, A., Crystal, W., Xu, J., Qin, Y., Reddy, V., Matthews, R., Owens, C., Okoli, J., Beech, D., Piyathilake, C., Reddy, S. and Rao, V., 2012. Triple Negative Breast Cancer – An Overview. *Hereditary Genetics*, 2(1).
- Banerji, U., Ashley, S., Coward, J., Hughes, S., Zee, Y., Benepal, T., Norton, A., Eisen, T. and O'Brien, M., 2006. The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. *Lung Cancer*, 54(3), pp.371-377.
- Bauer, K., Brown, M., Cress, R., Parise, C. and Caggiano, V., 2007. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2- negative invasive breast cancer, the so-called triple-negative phenotype. *Cancer*, 109(9), pp.1721-1728.
- Breastcancer.org. 2019. *Triple-Negative Breast Cancer: Overview, Treatment, and More*. [online] Available at: https://www.breastcancer.org/symptoms/diagnosis/trip_neg [Accessed 14 Nov. 2019].
- Breastcancer.org. 2019. *U.S. Breast Cancer Statistics | Breastcancer.org*. [online] Available at: https://www.breastcancer.org/symptoms/understand_bc/statistics [Accessed 14 Nov. 2019].
- Boxer, L. and Dale, D., 2002. Neutropenia: Causes and consequences. *Seminars in Hematology*, 39(2), pp.75-81.
- Carey, L., Dees, E., Sawyer, L., Gatti, L., Moore, D., Collichio, F., Ollila, D., Sartor, C., Graham, M. and Perou, C., 2007. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. *Clinical Cancer Research*, 13(8), pp.2329-2334.
- Chen, Z., Chen, W., Wang, J., Zhu, M. and Zhuang, Z., 2015. Pretreated baseline neutrophil count and chemotherapy-induced neutropenia may be conveniently available as prognostic biomarkers in advanced gastric cancer. *Internal Medicine Journal*, 45(8), pp.854-859.
- Chen, Y., Shi, Y., Yan, H., Wang, Y. and Dai, G., 2017. Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy. *Oncotarget*, 8(39).
- Chen, Y., Wang, Y., Shi, Y., & Dai, G., 2017. Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6-treated patients. *BMC cancer*, 17(1), 242.



- Collignon, J., Lousberg, L., Schroeder, H., & Jerusalem, G., 2016. Triple-negative breast cancer: treatment challenges and solutions. *Breast cancer (Dove Medical Press)*, 8, 93–107.
- Costa, R. L. & Gradishar, W. J., 2017. Triple-Negative Breast Cancer: Current Practice and Future Directions. *Journal of Oncology Practice*, 13(5), pp. 301-304.
- Crawford, J., Dale, D. and Lyman, G., 2004. Chemotherapy-induced neutropenia. *Cancer*, 100(2), pp.228-237.
- Dent, R., Trudeau, M., Pritchard, K., Hanna, W., Kahn, H., Sawka, C., Lickley, L., Rawlinson, E., Sun, P. and Narod, S., 2007. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. *Clinical Cancer Research*, 13(15), pp.4429-4434.
- Dillon, D. A., Guidi, A. J., Schnitt, S. J., 2009. Pathology of invasive breast cancer. *Diseases of the Breast*, 4th. Philadelphia: Lippincott, Williams and Wilkins, p. 386.
- Dong, Y. and Peng, C., 2013. Principled missing data methods for researchers. *SpringerPlus*, 2(1).
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2012. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. *The Lancet*, 279(9814), pp. 432 - 444.
- Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. and Parkin, D., 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International Journal of Cancer*, 127(12), pp.2893-2917.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D., Forman, D., and Bray, F., 2014. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*, 136(5), pp.E359-E386.
- Fisher, B., Anderson, S., Bryant, J., Margolese, R., Deutsch, M., Fisher, E., Jeong, J. and Wolmark, N., 2002. Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer. *New England Journal of Medicine*, 347(16), pp. 1233 - 1241.
- Fontanella, C., Bolzonello, S., Lederer, B. and Aprile, G., 2014. Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia. *Breast Care*, 9(4), pp.239-245.
- Ghozali, A., 2015. Registrasi Tumor Berbasis Data Laboratorium Patologi. Yogyakarta: RSUP Dr. Sardjito, Instalasi Patologi Anatomi.
- Han, Y., Yu, Z., Wen, S., Zhang, B., Cao, X. and Wang, X., 2011. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. *Breast Cancer Research and Treatment*, 131(2), pp.483-490.
- Iqbal, B. and Buch, A., 2016. Hormone receptor (ER, PR, HER2/neu) status and proliferation index marker (Ki-67) in breast cancers: Their onco-pathological correlation, shortcomings and future trends. *Medical Journal of Dr. D.Y. Patil University*, 9(6), p.674.
- Jakobsen, J., Gluud, C., Wetterslev, J. and Winkel, P., 2017. When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. *BMC Medical Research Methodology*, 17(1).
- Jang, S., Kim, S., Kim, J., Park, S., Hwang, Y., Kim, D. and Jung, K., 2012. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-

- small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients. *Journal of Cancer Research and Clinical Oncology*, 139(3), pp.409-417.
- Jensen, H., Donskov, F., Marcussen, N., Nordmark, M., Lundbeck, F. and von der Maase, H., 2009. Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma. *Journal of Clinical Oncology*, 27(28), pp.4709-4717.
- Kamińska, M., Ciszewski, T., Łopacka-Szatan, K., Miotła, P., & Starosławska, E., 2015. Breast cancer risk factors. *Przegląd menopauzalny = Menopause review*, 14(3), 196–202.
- Kang, H., 2013. The prevention and handling of the missing data. *Korean Journal of Anesthesiology*, 64(5), p.402.
- Kaplan, H. and Malmgren, J., 2008. Impact of Triple Negative Phenotype on Breast Cancer Prognosis. *The Breast Journal*, 14(5), pp.456-463.
- Kasi, P. and Grothey, A., 2018. Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients. *Drugs*, 78(7), pp.737-745.
- Kim, J., Choi, W. and Jeong, S., 2013. The Effects of Physical Activity on Breast Cancer Survivors after Diagnosis. *Journal of Cancer Prevention*, 18(3), pp.193-200.
- Kim, Y., Chung, H., Kim, J., Park, N., Song, Y. and Kang, S., 2009. Prognostic significance of neutropenia during adjuvant concurrent chemoradiotherapy in early cervical cancer. *Journal of Gynecologic Oncology*, 20(3), p.146.
- Kurihara, T., Kogo, M., Ishii, M., Shimada, K., Yoneyama, K., Kitamura, K., Shimizu, S., Yoshida, H. and Kiuchi, Y., 2015. Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer. *Cancer Chemotherapy and Pharmacology*, 76(6), pp.1217-1224.
- Lee, J., Kim, K., Bae, J., Jung, Y., An, H. and Lee, E., 2010. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. *Breast Cancer Research and Treatment*, 123(1), pp.177-187.
- Li, C., Uribe, D. and Daling, J., 2005. Clinical characteristics of different histologic types of breast cancer. *British Journal of Cancer*, 93(9), pp.1046-1052.
- Liu, R., Huang, M., Zhao, X., Peng, W., Sun, S., Cao, J., Ji, D., Wang, C., Guo, W., Li, J., Yin, J. and Zhu, X., 2015. Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen. *Oncotarget*, 6(36), pp.39018-39027.
- Lustberg, M. B., 2012. Management of Neutropenia in Cancer Patients. *HHS Public Access*, 10(12), pp.825–826
- Lyman, G., 2005. Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence. *Journal of the National Comprehensive Cancer Network*, 3(4), pp.557-571.
- Ma, R., Chen, C., Zhang, W., You, J., Huang, D. and Guo, G., 2016. Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer. *Medicine*, 95(13), p.e3240.
- Makki, J., 2015. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clinical Medicine Insights: Pathology*, 8, p.CPath.S31563.
- Madley-Dowd, P., Hughes, R., Tilling, K. and Heron, J., 2019. The proportion of missing data should not be used to guide decisions on multiple imputation. *Journal of Clinical Epidemiology*, 110, pp.63-73.

- Momenimovahed, Z. and Salehiniya, H., 2019. Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer: Targets and Therapy*, Volume 11, pp.151-164.
- Morris, G., Naidu, S., Topham, A., Guiles, F., Xu, Y., McCue, P., Schwartz, G., Park, P., Rosenberg, A., Brill, K. and Mitchell, E., 2007. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients. *Cancer*, 110(4), pp.876-884.
- Moore, D., 2016. Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia. PHARMACOVIGILANCE FORUM, [online] 41(12), pp.765 - 766. Available at: <https://pubmed.ncbi.nlm.nih.gov/27990078/> [Accessed 25 August 2020].
- Nakai, K., Hung, M. C., & Yamaguchi, H., 2016. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. *American journal of cancer research*, 6(8), 1609–1623.
- Nishimura, R. and Arima, N., 2008. Is triple negative a prognostic factor in breast cancer?. *Breast Cancer*, 15(4), pp.303-308.
- Ostapenko, V., Pipirienė Želvienė, T., Smailytė, G., Ostapenko, A. and Meškauskas, R., 2014. Triple negative breast cancer: 5-year results of combined treatment. *Acta medica Lituanica*, 20(4).
- Ovcaricek, T., Frkovic, S., Matos, E., Mozina, B. and Borstnar, S., 2011. Triple negative breast cancer - prognostic factors and survival. *Radiology and Oncology*, 45(1).
- Ozsoy, A., Barca, N., Akdal Dolek, B., Aktas, H., Elverici, E., Araz, L. and Ozkaraoglu, O., 2017. The Relationship Between Breast Cancer and Risk Factors: A Single-Center Study. *European Journal of Breast Health*, 13(3), pp.145-149.
- Rahmawati, Y., Setyawati, Y., Widodo, I., Ghozali, A., & Purnomosari, D., 2018. Molecular Subtypes of Indonesian Breast Carcinomas - Lack of Association with Patient Age and Tumor Size. *Asian Pacific journal of cancer prevention: APJCP*, 19(1), pp161–166.
- Rocconi, R., Matthews, K., Kemper, M., Hoskins, K. and Barnes, M., 2008. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. *Gynecologic Oncology*, 108(2), pp.336-341.
- Rodler, E., Korde, L. and Gralow, J., 2011. Current treatment options in triple negative breast cancer. *Breast Disease*, 32(1-2), pp.99-122.
- Rouzier, R., 2005. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. *Clinical Cancer Research*, 11(16), pp.5678-5685.
- Rubin, D., 1976. *Inference And Missing Data*. 3rd ed. Biometrika 63.
- Sastroasmoro, Prof.Dr.Sudigdo dan Ismail, Prof.Dr.Sofyan, 2011. *Dasar-Dasar Metodologi Penelitian Klinis*. 4th ed. Jakarta: Sagung Seto
- Schwartzberg, L., 2006. Neutropenia: Etiology and Pathogenesis. *Clinical Cornerstone*, 8, pp.S5-S11.
- Sun, Y., Zhao, Z., Yang, Z., Xu, F., Lu, H., Zhu, Z., Shi, W., Jiang, J., Yao, P. and Zhu, H., 2017. Risk Factors and Preventions of Breast Cancer. *International Journal of Biological Sciences*, 13(11), pp.1387-1397.
- Sunaga, T., Suzuki, S., Kogo, M., Kurihara, T., Kaji, S., Koike, N., Harada, N., Suzuki, M. and Kiuchi, Y., 2013. The association between neutropenia and prognosis in stage III colorectal

- cancer patients receiving adjuvant chemotherapy. *European Journal of Cancer Care*, 23(3), pp.394-400.
- Tariq, 2013. TNBC vs. Non-TNBC: A Five-Year Retrospective Review of Differences in Mean Age, Family History, Smoking History and Stage at Diagnosis at an Inner City University Program. *World Journal of Oncology*.
- Tewari, K., Java, J., Gatliffe, T., Bookman, M. and Monk, B., 2014. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group. *Gynecologic Oncology*, 133(3), pp.439-445.
- Urru, S., Gallus, S., Bosetti, C., Moi, T., Medda, R., Sollai, E., Murgia, A., Sanges, F., Pira, G., Manca, A., Palmas, D., Floris, M., Asunis, A., Atzori, F., Carru, C., D'Incalci, M., Ghiani, M., Marras, V., Onnis, D., Santona, M., Sarobba, G., Valle, E., Canu, L., Cossu, S., Bulfone, A., Rocca, P., De Miglio, M. and Orrù, S., 2018. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. *BMC Cancer*, 18(1).
- Verma, S., Provencher, L., & Dent, R., 2011. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. *Current oncology (Toronto, Ont.)*, 18(4), pp.180-190.
- Vila, J., Gandini, S. and Gentilini, O., 2015. Overall survival according to type of surgery in young (≤ 40 years) early breast cancer patients: A systematic meta-analysis comparing breast-conserving surgery versus mastectomy. *The Breast*, 24(3), pp.175-181.
- Wahba, H. A., El-Hadaad, H. E., 2015. Current approaches in treatment of triple-negative breast cancer. *Special Issue on Immunotherapy for Lung Cancer*, 12(2).
- Wang, C., Kar, S., Lai, X., Cai, W., Arfuso, F., Sethi, G., Lobie, P., Goh, B., Lim, L., Hartman, M., Chan, C., Lee, S., Tan, S. and Kumar, A., 2018. Triple negative breast cancer in Asia: An insider's view. *Cancer Treatment Reviews*, 62, pp.29-38.
- Wang, Y., Chen, Y., Yin, H., Gu, X., Shi, Y. and Dai, G., 2018. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first-line chemotherapy with oxaliplatin and capecitabine: a retrospective study. *Cancer Medicine*, 7(4), pp.997-1005.
- Yamanaka, T., Matsumoto, S., Teramukai, S., Ishiwata, R., Nagai, Y. and Fukushima, M., 2007. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. *British Journal of Cancer*, 97(1), pp.37-42.
- Yuan, N., Meng, M., Liu, C., Feng, L., Hou, L., Ning, Q., Xin, G., Pei, L., Gu, S., Li, X. and Zhao, X., 2013. Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. *Molecular and Clinical Oncology*, 2(2), pp.245-251.
- Zhu, W. and Xu, B., 2015. Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study. *PLOS ONE*, 10(8), p.e0136268.